Regen BioPharma Inc (RGBP)

[tcubed]

Updates from Koos on twitter...

https://mobile.twitter.com/theregenbio

Regen's complete 8K: https://t.co/ExrkecBGZN

On May 16, 2022 Regen Biopharma, Inc. issued 100,000,000 common shares (“Shares”) to Coventry Enterprises LLC in satisfaction of $334,800 of convertible indebtedness. The principal balance remaining on the $1,5M note issued to Coventry Enterprises LLC is $648,001 $RGBP $RGBPP

Additionally, Regen has other NR2F6 chemical matter which is also being evaluated by the U.S. Patent Office. The Company wants to grow our intellectual property portfolio around immunotherapy as aggressively as It can. $RGBP $RGBPP

KCL Therapeutics, Inc., a wholly-owned subsidiary of Regen BioPharma, Inc. has been granted patent protection by the U.S. Patent and Trademark Office for the application titled “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans.” $RGBP $RGBPP

Regen has spent a lot of time, effort and money developing small molecules that can potentially be used to modulate the immune system $RGBP $RGBPP

This issued patent contains multiple composition of matter claims reflecting various chemical entities that modulate NR2F6. The experiments which led to the discovery of these structures was performed by a contract research organization under the direction of Regen and KCL.

Cheers

tcubed